PE20120713A1 - Composiciones sublinguales de dexmedetomidina y metodos para su uso - Google Patents

Composiciones sublinguales de dexmedetomidina y metodos para su uso

Info

Publication number
PE20120713A1
PE20120713A1 PE2011001958A PE2011001958A PE20120713A1 PE 20120713 A1 PE20120713 A1 PE 20120713A1 PE 2011001958 A PE2011001958 A PE 2011001958A PE 2011001958 A PE2011001958 A PE 2011001958A PE 20120713 A1 PE20120713 A1 PE 20120713A1
Authority
PE
Peru
Prior art keywords
dexmedetomidine
methods
pharmaceutically acceptable
hydrochloride
sublingual
Prior art date
Application number
PE2011001958A
Other languages
English (en)
Spanish (es)
Inventor
Geraldine Anne Henwood
Randall Jerome Mack
Christopher Thomas Sharr
Jr John Joseph Koleng
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of PE20120713A1 publication Critical patent/PE20120713A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0625—Mouth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2011001958A 2009-05-15 2010-05-17 Composiciones sublinguales de dexmedetomidina y metodos para su uso PE20120713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15

Publications (1)

Publication Number Publication Date
PE20120713A1 true PE20120713A1 (es) 2012-07-08

Family

ID=43085620

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001958A PE20120713A1 (es) 2009-05-15 2010-05-17 Composiciones sublinguales de dexmedetomidina y metodos para su uso

Country Status (21)

Country Link
US (1) US20110021588A1 (enExample)
EP (2) EP2429521B1 (enExample)
JP (2) JP6172938B2 (enExample)
KR (1) KR101859486B1 (enExample)
CN (2) CN106511273A (enExample)
AU (1) AU2010248776B2 (enExample)
BR (1) BRPI1010567A2 (enExample)
CA (1) CA2762107A1 (enExample)
CL (1) CL2011002858A1 (enExample)
CO (1) CO6460767A2 (enExample)
CR (1) CR20110596A (enExample)
DO (1) DOP2011000354A (enExample)
EC (1) ECSP11011459A (enExample)
HN (1) HN2011003011A (enExample)
IL (1) IL216159A (enExample)
MX (1) MX2011011950A (enExample)
NZ (1) NZ596976A (enExample)
PE (1) PE20120713A1 (enExample)
RU (1) RU2572692C2 (enExample)
SG (1) SG175979A1 (enExample)
WO (1) WO2010132882A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
JP6268100B2 (ja) * 2011-12-11 2018-01-24 レクロ・ファーマ，インコーポレーテッド 鼻腔内デクスメデトミジン組成物およびその使用方法
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
CN104797252B (zh) * 2012-10-15 2016-09-21 奥赖恩公司 减轻噪音厌恶的兽医方法
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
KR20180095732A (ko) * 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
HUE055565T2 (hu) * 2016-12-13 2021-11-29 Orion Corp Dexmedetomidin vagy medetomidin alkalmazása a szeparációs szorongás kezelésében kedvtelésbõl tartott állatoknál
EP3562486B1 (en) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
EP3813802B1 (en) 2018-06-27 2024-10-23 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
AU2020316013A1 (en) * 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
EP4583871A1 (en) * 2022-09-11 2025-07-16 BioXcel Therapeutics, Inc. Methods for treating agitation in community settings
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE10299002I1 (de) * 1990-12-05 2012-07-05 Gen Hospital Corp Verwendung von No zur Behandlung oder Praevention der Bronchokonstriktion
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
HUP0103543A2 (hu) * 1998-10-02 2002-01-28 3M Innovative Properties Company Nyálkahártyán megtapadó hatóanyag bejuttató rendszerek és ezek alkalmazása állatok kezelésére
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8486972B2 (en) * 2006-01-25 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
ES2624577T3 (es) * 2006-02-13 2017-07-17 Orient Pharma (Samoa) Co. Ltd. Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
US20080021074A1 (en) * 2006-06-29 2008-01-24 Questcor Pharmaceuticals, Inc. Pharmaceutical Compositions and Related Methods of Treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Also Published As

Publication number Publication date
CO6460767A2 (es) 2012-06-15
EP2429521A2 (en) 2012-03-21
MX2011011950A (es) 2012-02-21
HN2011003011A (es) 2014-12-01
DOP2011000354A (es) 2012-07-15
CL2011002858A1 (es) 2012-06-22
JP2012526854A (ja) 2012-11-01
CN106511273A (zh) 2017-03-22
WO2010132882A3 (en) 2011-03-31
EP3305281A1 (en) 2018-04-11
IL216159A0 (en) 2012-01-31
KR20120008058A (ko) 2012-01-25
US20110021588A1 (en) 2011-01-27
CR20110596A (es) 2012-03-26
RU2572692C2 (ru) 2016-01-20
CA2762107A1 (en) 2010-11-18
IL216159A (en) 2015-10-29
EP2429521B1 (en) 2017-10-18
ECSP11011459A (es) 2012-01-31
EP2429521A4 (en) 2013-08-21
AU2010248776A1 (en) 2012-01-12
JP6172938B2 (ja) 2017-08-02
JP2016029055A (ja) 2016-03-03
RU2011151059A (ru) 2013-06-20
KR101859486B1 (ko) 2018-06-28
NZ596976A (en) 2014-05-30
WO2010132882A2 (en) 2010-11-18
SG175979A1 (en) 2011-12-29
CN102639131A (zh) 2012-08-15
BRPI1010567A2 (pt) 2016-03-15
WO2010132882A8 (en) 2011-12-29
AU2010248776B2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
PH12015501156A1 (en) Pharmaceutical compositions
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX340985B (es) Compuestos de n-heteroarilo.
AU2011336397A8 (en) Chemokine CXCR4 receptor modulators and uses related thereto
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
WO2015009731A3 (en) Azacyclic constrained analogs of fty720

Legal Events

Date Code Title Description
FC Refusal